X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADP101 is a potentially best-in-class oral immunotherapy (OIT) designed to desensitize patients allergic to one or multiple foods simultaneously to mitigate risk of severe, life-threatening food-allergic reactions.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
The capital will be used to further support the clinical development of Alladapt’s lead asset ADP101 through initiation of a potential Phase 3 pivotal trial, as well as the completion of its manufacturing facility.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 30, 2022
Details:
Alladapt in their important goal of developing a single therapeutic ADP101, to address a wide range of mono- and multi-food allergies, and looking forward to fulfilling their Phase III and commercial requirements.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Altasciences Company Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2022
Details:
Proceeds will support the ongoing clinical development of ADP101, the Company’s lead product candidate, as well as preparation for a potential pivotal trial, the continued buildout of Alladapt’s manufacturing facility, and investment in further pipeline expansion.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Enavate Sciences
Deal Size: $119.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 22, 2022
Details:
ADP101 is a potentially best-in-class oral immunotherapy (OIT) designed to desensitize patients allergic to one or multiple foods simultaneously to mitigate risk of severe, life-threatening food-allergic reactions.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
ADP101 is an investigational oral immunotherapy product candidate representing the nine food groups responsible for the vast majority of significant food allergic reactions.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
